ArticleTherapeutic advances in medical oncology2025
Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.Oncoimmunology · 2026Article
- Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.British journal of cancer · 2026Article
- Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors.British journal of cancer · 2026Article
- Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Chrono-immunotherapy's current and future optimization strategies: immunotherapy timing in line with the circadian rhythm brings longer survival benefits.Frontiers in immunology · 2026Review
- Early time-of-day infusion of PD-1 inhibitor improves prognosis in advanced gastric cancer: a multicenter real-world study.Frontiers in immunology · 2026Article
- Circadian Rhythms in Gastroenterology: The Biological Clock's Impact on Gut Health.Gastroenterology · 2025Review
- Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study.EBioMedicine · 2025Article
- Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy.Cancers · 2025Review
- Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis.Frontiers in immunology · 2025Article
- Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?British journal of cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors are used either as monotherapy or in combination with cytotoxic agents in metastatic gastric cancer (mGC). Studies show that circadian rhythms are essential for immune system functions, including anticancer immunity. Objectives: This study evaluated whether the time of day of nivolumab infusion altered the efficacy of mGC treatment. Design: This was a retrospective cohort study. Methods: We retrospectively analyzed the data of 296 consecutive patients with mGC who received nivolumab monotherapy between December 2014 and December 2022. Patients were divided into early (EA)- and late (LA)-nivolumab infusion groups: the EA and LA groups received ⩾70% and <70% of their infusions before 14:00, respectively. Treatment efficacy was compared between the groups. Results: A total of 248 patients were eligible: 140 and 108 in the EA and LA groups, respectively. Most baseline characteristics were similar between the groups, except for differences in the neutrophil-to-lymphocyte ratio. The progression-free survival (PFS) and overall survival (OS) were significantly better in the EA than in the LA group (median PFS, 2.3 vs 1.6 months; hazard ratio (HR), 0.65; Conclusion: Our data suggest that scheduling nivolumab infusions before mid-afternoon should be considered in daily practice for the treatment of mGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.